Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: Is PSA a useful indicator of clinical significance?

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 1, 2004, Pages 40-47

  Ward, John F ^a   Bartsch, George ^b   Sebo, Thomas J ^a   Pinggera, Germar Michael ^b   Blute, Michael L ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Clinical markers; Mass screening; Prognosis; Prostate specific antigen; Prostatic neoplasms; Treatment outcome

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUSTRIA; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CELL PROLIFERATION; CYTOPROSTATECTOMY; DNA CONTENT; HUMAN; HUMAN TISSUE; MALE; MEDICAL EXAMINATION; MICROSCOPY; MORPHOMETRICS; PLOIDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SURGICAL TECHNIQUE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 2142825659     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00093-0     Document Type: Article

References (44)

1. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 71:(Suppl 3):1993;933-938
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. [comment] CA Cancer J Clin. 49:(1):1999;8-31
3. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of a human prostate specific antigen. Invest Urol. 17:(2):1979;159-163
4. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:(17):1991;1156-1161. [erratum appears in N Engl J Med 1991;325(18):1324]
5. Cooner W.H., Mosley B.R., Rutherford C.L., et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 143:(6):1990;1146-1152. discussion 52-4
6. Carroll P., Coley C., McLeod D., et al. Prostate-specific antigen best practice policy - part I early detection and diagnosis of prostate cancer. Urology. 52:(2):2001;217-224
7. Maattanen L., Auvinen A., Stenman U.H., et al. European randomized study of prostate cancer screening first-year results of the Finnish trial. Br J Cancer. 79:(7-8):1999;1210-1214
8. Lodding P., Aus G., Bergdahl S., et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. [comment] J Urol. 159:(3):1998;899-903
9. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. [see comments] JAMA. 277:(18):1997;1452-1455
10. Reissigl A., Horninger W., Fink K., Klocker H., Bartsch G. Prostate carcinoma screening in the county of Tyrol, Austria experience and results. Cancer. 80:(9):1997;1818-1829
11. Fleming I.D. AJCC cancer staging manual/American Joint Committee on Cancer. 5th ed. 1997;Lippincott-Raven, Philadelphia
12. Gleason D.F. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 111:(1):1974;58-64
13. Humphrey P.A., Vollmer R.T. Intraglandular tumor extent and prognosis in prostatic carcinoma application of a grid method to prostatectomy specimens. Human Pathol. 21:(8):1990;799-804
14. Sebo T.J. Digital image analysis. Mayo Clinic Proceed. 70:(1):1995;81-82
15. Bacus J.W., Bacus J.V. A method of correcting DNA ploidy measurements in tissue sections. Mod Pathol. 7:(6):1994;652-664
16. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. [comment] JAMA. 271:(5):1994;368-374
17. Dugan J.A., Bostwick D.G., Myers R.P., Qian J., Bergstralh E.J., Oesterling J.E. The definition and preoperative prediction of clinically insignificant prostate cancer. [comment] JAMA. 275:(4):1996;288-294
18. Djavan B., Mazal P., Zlotta A., et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy results of the prospective European Prostate Cancer Detection study. Prostate. 47:(2):2001;111-117
19. Sebo T.J., Cheville J.C., Riehle D.L., et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol. 26:(4):2002;431-439
20. Lieber M.M. Prognostic importance of nuclear DNA content measured by flow cytometry for patients with adenocarcinoma of the prostate. Urologia Internationalis. 47:(Suppl 1):1991;74-76
21. Bostwick D.G., Montironi R. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Pathol Res Prac. 191:(9):1995;828-832
22. Breslow N., Chan C.W., Dhom G., et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 20:(5):1977;680-688
23. Franks L.M. Latent carcinoma of the prostate. J Pathol. 68:1954;603-616
24. McNeal J.E. Origin and development of carcinoma of the prostate. Cancer. 23:1969;24-34
25. McNeal J.E., Bostwick D.G., Kindrachuk R.A., Redwine E.A., Freiha F.S., Stamey T.A. Patterns of progression in prostate cancer. Lancet. 1:(8472):1986;60-63
26. Stamey T.A., McNeal J.E., Freiha F.S., Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol. 139:(6):1988;1235-1241
27. Villers A.A., McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol. 143:(6):1990;1183-1187
28. McNeal J.E. Cancer volume and site of origin of adenocarcinoma in the prostate relationship to local and distant spread. Human Pathol. 23:(3):1992;258-266
29. Terris M.K., Haney D.J., Johnstone I.M., McNeal J.E., Stamey T.A. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 45:(1):1995;75-80
30. Irwin M.B., Trapasso J.G. Identification of insignificant prostate cancers analysis of preoperative parameters. Urology. 44:(6):1994;862-867. discussion 67-8
31. Csapo Z., Brand K., Walther R., Fokas K. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J Urol. 140:(5):1988;1032-1038
32. Schmid H.P., McNeal J.E., Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 71:(6):1993;2031-2040
33. Stamey T.A., Johnstone I.M., McNeal J.E., Lu A.Y., Yemoto C.M. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol. 167:(1):2002;103-111
34. Brawer M.K., Stamey T.A., Fowler J., Droller M., Messing E., Fair W.R. Perspectives on prostate cancer diagnosis and treatment a roundtable. Urology. 58:(2):2001;135-140
35. Noldus J., Stamey T.A. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. [comment] J Urol. 155:(1):1996;232-237
36. Roehrborn C.G., Boyle P., Gould A.L., Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 53:(3):1999;581-589
37. Wright E.J., Fang J., Metter E.J., et al. Prostate specific antigen predicts the long-term risk of prostate enlargement results from the Baltimore Longitudinal Study of Aging. J Urol. 167:(6):2002;2484-2487. discussion 87-8
38. Catalona W.J., Hudson M.A., Scardino P.T., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer receiver operating characteristic curves. [see comments] J Urol. 152:(6 Pt 1):1994;2037-2042
39. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. [see comments] JAMA. 270:(7):1993;860-864
40. Harris C.H., Dalkin B.L., Martin E., Marx P.C., Ahmann F.R. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/ml or less. [comment] J Urol. 157:(5):1997;1740-1743
41. McNaughton Collins M., Ransohoff D.F., Barry M.J. Early detection of prostate cancer. Serendipity strikes again. [comment] JAMA. 278:(18):1997;1516- 1519
42. Sebo T.J., Cheville J.C., Riehle D.L., Lohse C.M., Pankratz V.S., Myers R.P., Blute M.L., Zincke H. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen a report of 454 cases. Cancer. 91:(11):2001;2196-2204
43. Bostwick D.G. Prostatic intraepithelial neoplasia (PIN). Urology. 34:(Suppl 6):1989;16-22
44. Bostwick D.G. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol. 30:(2):1996;145-152